[go: up one dir, main page]

TR201009398A2 - Fiziksel özellikleri geliştirilmiş tablet formülasyonları - Google Patents

Fiziksel özellikleri geliştirilmiş tablet formülasyonları

Info

Publication number
TR201009398A2
TR201009398A2 TR2010/09398A TR201009398A TR201009398A2 TR 201009398 A2 TR201009398 A2 TR 201009398A2 TR 2010/09398 A TR2010/09398 A TR 2010/09398A TR 201009398 A TR201009398 A TR 201009398A TR 201009398 A2 TR201009398 A2 TR 201009398A2
Authority
TR
Turkey
Prior art keywords
physical properties
improved physical
tablet formulations
locotriene
antihistaminic
Prior art date
Application number
TR2010/09398A
Other languages
English (en)
Inventor
Bi̇lgi̇ç Mahmut
Original Assignee
Bi̇lgi̇ç Mahmut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bi̇lgi̇ç Mahmut filed Critical Bi̇lgi̇ç Mahmut
Priority to TR2010/09398A priority Critical patent/TR201009398A2/tr
Priority to PCT/TR2011/000247 priority patent/WO2012064305A2/en
Priority to PCT/TR2011/000243 priority patent/WO2012064301A2/en
Publication of TR201009398A2 publication Critical patent/TR201009398A2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Mevcut buluş, derinin veya ust ve alt solunum yollarının alerjik ve inflamatuar hastalıklarının önlenmesi ve/veya tedavisinde ve bu hastalıklarla ilişkili semptomların giderilmesinde etkili bir Hı-antihıstamınik ve lokotrien reseptör antagonistı kombinasyonunu içermektedir.
TR2010/09398A 2010-11-11 2010-11-11 Fiziksel özellikleri geliştirilmiş tablet formülasyonları TR201009398A2 (tr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
TR2010/09398A TR201009398A2 (tr) 2010-11-11 2010-11-11 Fiziksel özellikleri geliştirilmiş tablet formülasyonları
PCT/TR2011/000247 WO2012064305A2 (en) 2010-11-11 2011-11-03 Formulations with improved physical characteristics
PCT/TR2011/000243 WO2012064301A2 (en) 2010-11-11 2011-11-03 Physically improved tablet formulations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2010/09398A TR201009398A2 (tr) 2010-11-11 2010-11-11 Fiziksel özellikleri geliştirilmiş tablet formülasyonları

Publications (1)

Publication Number Publication Date
TR201009398A2 true TR201009398A2 (tr) 2012-05-21

Family

ID=45446164

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2010/09398A TR201009398A2 (tr) 2010-11-11 2010-11-11 Fiziksel özellikleri geliştirilmiş tablet formülasyonları

Country Status (2)

Country Link
TR (1) TR201009398A2 (tr)
WO (2) WO2012064301A2 (tr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2802853C (en) 2010-06-16 2016-07-26 Bruce Chandler May Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation
RU2677649C2 (ru) * 2013-02-21 2019-01-18 Глэнмарк Фармасьютикалс Лимитед Фармацевтические композиции монтелукаста и левоцетиризина
CA2901413A1 (en) 2013-03-13 2014-10-09 Bruce Chandler May Use of levocetirizine and montelukast in the treatment of vasculitis
CN105517631A (zh) * 2013-03-13 2016-04-20 炎症反应研究公司 左西替利嗪和孟鲁司特在治疗创伤性损伤中的用途
ES2654093T3 (es) 2013-03-13 2018-02-12 Inflammatory Response Research, Inc. Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes
CN106456535B (zh) 2014-04-25 2020-07-03 R.P.谢勒技术有限公司 稳定的孟鲁司特溶液
WO2016044095A1 (en) 2014-09-15 2016-03-24 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of inflammation mediated conditions
EP3222279B1 (en) 2016-03-21 2021-11-17 Invest Bielany Spolka z ograniczona odpowiedzialnoscia Oral pharmaceutical formulation of montelukast and levocetirizine and method for its production
WO2017210417A1 (en) * 2016-06-03 2017-12-07 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of radiation-mediated conditions
KR102110304B1 (ko) * 2017-06-30 2020-05-14 한미약품 주식회사 레보세티리진 및 몬테루카스트를 포함하는 안정성 및 복약순응도가 향상된 복합 츄어블정 및 그 제조방법
MX2018011699A (es) * 2018-09-26 2019-07-24 Federico Amezcua Amezcua Composicion farmaceutica sinergica de un antagonista de los receptores de leucotrienos y un agonista inverso de la histamina h1.
KR20210114962A (ko) * 2019-01-10 2021-09-24 장인 무코케어 파마슈티컬 컴퍼니 리미티드 류코트리엔 수용체 길항제를 함유하는 신규 제제
US12514855B2 (en) 2020-05-19 2026-01-06 IRR, Inc. Levocetirizine and montelukast in the treatment of sepsis and symptoms thereof
CN117320697A (zh) * 2021-10-21 2023-12-29 韩和制药株式会社 包含孟鲁司特或其药学上可接受的盐和左西替利嗪或其药学上可接受的盐的稳定性提高的薄膜包衣片剂

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO155805C (no) 1981-02-06 1987-06-10 Ucb Sa Analogifremgangsmaate for fremstilling av terapeutisk virksomme 2-(4-(difenylmethyl)-1-piperazinyl)-eddiksyrer og deres amider og ikke-toksiske salter.
GB8827391D0 (en) 1988-11-23 1988-12-29 Ucb Sa Process for preparation of 2-(2-(4-((4-chlorophenyl)phenylmethyl)-1-pipera-zinyl)ethoxy)-acetic acid & its dihydrochloride
ATE165088T1 (de) 1990-10-12 1998-05-15 Merck Frosst Canada Inc Ungesättigte hydroxyalkylchinolinsäuren als leukotrien-antagonisten
JPH08501561A (ja) 1992-09-24 1996-02-20 セプラコア，インコーポレイテッド （−）セチリジンを用いたアレルギー疾患の治療のための組成物
AU2003264859A1 (en) 2001-12-21 2003-12-19 Sampad Bhattacharya Intranasal pharmaceutical compositions comprising an antihistamine and a leukotriene inhibitor
EA021960B1 (ru) * 2005-12-30 2015-10-30 Крка, Товарна Здравил, Д.Д., Ново Место Таблетка, содержащая фармацевтически приемлемую соль монтелукаста в аморфной форме, и способ ее получения
WO2007092031A1 (en) 2006-02-09 2007-08-16 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical formulations of montelukast sodium
US20090124657A1 (en) * 2007-08-14 2009-05-14 Ramesh Kappala Pharmaceutical compositions comprising montelukast
WO2009122187A2 (en) * 2008-04-03 2009-10-08 Cipla Limited Pharmaceutical composition
WO2010107404A1 (en) * 2009-03-16 2010-09-23 Mahmut Bilgic Stable pharmaceutical combinations

Also Published As

Publication number Publication date
WO2012064305A2 (en) 2012-05-18
WO2012064305A3 (en) 2012-08-09
WO2012064301A3 (en) 2012-07-19
WO2012064301A2 (en) 2012-05-18

Similar Documents

Publication Publication Date Title
TR201009398A2 (tr) Fiziksel özellikleri geliştirilmiş tablet formülasyonları
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
MX366018B (es) Composiciones de células t deficientes del receptor de células t.
UA104663C2 (xx) Антитіло, що зв'язує cd127$антитело, связывающее cd127
PH12014502577A1 (en) Compositions comprising an anti-pdgf aptamer and a vegf antagonist
CO6440531A2 (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
IL234508B (en) Inhalation of nitric oxide for treating respiratory diseases
IT1401979B1 (it) Dispositivo biomedico per la riabilitazione robotizzata dell'arto superiore umano, particolarmente per la riabilitazione neuromotoria dell'articolazione della spalla e del gomito.
WO2015031808A3 (en) Diagnostic methods and compositions for treatment of glioblastoma
JO3462B1 (ar) أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
DK2800581T3 (da) Fremgangsmåder til behandling af adfærdssymptomer på neurologiske og mentale forstyrrelser
CR20110658A (es) Antagonistas de la trayectoria hedgehog de ftalazina desustituida
SMT201600078B (it) Antagonista del recettore per cgrp
IL221873A (en) Pyrimidine derivatives and their use in the treatment of respiratory diseases such as copd
CU24133B1 (es) Polipéptidos que se enlazan a dr5 humana con efectos agonistas, que comprenden uno o más monómeros de un único dominio variable, utiles en el tratamiento de enfermedades y trastornos asociados con dr5
LT4104824T (lt) Kompozicijos, skirtos panaudoti taikant pacientams su didele širdies ir kraujagyslių ligos rizika antsvorio ir nutukimo gydymo būdą
WO2013160317A3 (en) Crhr1 antagonists for use in the treatment of patients having crh overactivity
EA201390977A1 (ru) Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона
DK3065764T6 (da) Mini-gastrin-analog, især til anvendelse i CCK-2-receptor-positive tumordiagnoser og/eller -behandling
PT2501234T (pt) Métodos e composições para o tratamento de sintomas associados com distúrbios de stress pós-traumático utilizando ciclobenzaprina
IL312551A (en) Grpr-antagonists for detection, diagnosis and treatment of grpr-positive cancer
BR112012030331A2 (pt) isoformas de neuregulin, polipeptídeos de neuregulin, e usos dos mesmos
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
TR201909158T4 (tr) siRNA ve göz rahatsızlıklarının tedavisi ve/veya önlenmesine yönelik yöntemler ve bileşimlerde kullanımları.
EA201491532A1 (ru) Фармацевтические композиции для использования в комплексной терапии